Objective:

To evaluate the efficacy and safety of a paclitaxel-coated balloon in treating coronary small vessel disease (RVD ≤ 2.5 mm) and very small vessel disease (RVD < 2.0 mm).

Approach:

Key Findings:

• DCB showed lower in-lesion late lumen loss compared to everolimus-eluting stents (p-value needed).
• DCB demonstrated superior angiographic efficacy in patients with very small vessel disease (p-value needed).
• The study supports DCB as a viable treatment option for small vessel disease.

Interpretation:

The findings suggest that paclitaxel-coated balloons may provide a safer and more effective alternative to drug-eluting stents in treating small vessel disease.

Limitations:

• The study was limited to specific patient populations and may not be generalizable to all coronary artery disease patients, particularly those outside the defined RVD range.
• Potential biases in patient selection and treatment assignment should be acknowledged and discussed.

Conclusion:

Paclitaxel-coated balloons are effective and safe for treating coronary small vessel disease, offering a promising alternative to traditional stenting methods.

Source

Based on findings from:

Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study

Mingduo Zhang, Shiqi Liu, Zhao Ma, Meichen Sun, Yifei Nie, Baoen Zhang, Min Zhang, Xiantao Song, Dongfeng Zhang. Bmc Cardiovascular Disorders, 2026.

https://link.springer.com/article/10.1186/s12872-026-05723-x

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.